Background: Intraoperative visualization of pancreatic tumors has the potential to improve radical resection rates. Intraoperative visualization of the common bile duct and bile duct anastomoses could be of added value. In this study, we explored the use of indocyanine green (ICG) for these applications and attempted to optimize injection timing and dose. Methods: Eight patients undergoing a pancreaticoduodenectomy were injected intravenously with 5 or 10 mg ICG. During and after injection, the pancreas, tumor, common bile duct and surrounding organs were imaged in real time using the Mini-FLARE™ near-infrared (NIR) imaging system. Results: No clear tumor-to-pancreas contrast was observed, except for incidental contrast in 1 patient. The common bile duct was clearly visualized using NIR fluorescence, within 10 min after injection, with a maximal contrast between 30 and 90 min after injection. Patency of biliary anastomoses could be visualized due to biliary excretion of ICG. Conclusion: No useful tumor demarcation could be visualized in pancreatic cancer patients after intravenous injection of ICG. However, the common bile duct and biliary anastomoses were clearly visualized during the observation period. Therefore, these imaging strategies could be beneficial during biliary surgery in cases where the surgical anatomy is aberrant or difficult to identify.

Keywords:
Pancreatic surgery, Near-infrared fluorescence imaging, Indocyanine green, Bile duct imaging, Bile duct reconstruction, Image-guided surgery
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
2.
Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821–831.
3.
Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.
4.
Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004;198:722–731.
5.
Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273–279.
6.
Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP: Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008;9:99–132.
7.
Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K: Diagnosis of pancreatic cancer. HPB (Oxford) 2006;8:337–342.
8.
Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB: Intraoperative ultrasound of the pancreas. Ultrasound Q 2009;25:39–48.
9.
Sun MR, Brennan DD, Kruskal JB, Kane RA: Intraoperative ultrasonography of the pancreas. Radiographics 2010;30:1935–1953.
10.
Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56–61.
11.
Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195–200.
12.
Westerdahl J, Andren-Sandberg A, Ihse I: Recurrence of exocrine pancreatic cancer – local or hepatic? Hepatogastroenterology 1993;40:384–387.
13.
Keereweer S, Kerrebijn JD, van Driel PB, Xie B, Kaijzel EL, Snoeks TJ, Que I, Hutteman M, van der Vorst JR, Mieog JS, Vahrmeijer AL, van de Velde CJ, Baatenburg de Jong RJ, Lowik CW: Optical image-guided surgery – where do we stand? Mol Imaging Biol 2011;13:199–207.
14.
Frangioni JV: New technologies for human cancer imaging. J Clin Oncol 2008;26:4012–4021.
15.
Gioux S, Choi HS, Frangioni JV: Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging 2010;9:237–255.
16.
Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J: Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008;14:3840–3849.
17.
Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY: Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101:17867–17872.
18.
Hutteman M, Mieog JS, van der Vorst JR, Dijkstra J, Kuppen PJ, van der Laan AM, Tanke HJ, Kaijzel EL, Que I, van de Velde CJ, Lowik CW, Vahrmeijer AL: Intraoperative near-infrared fluorescence imaging of colorectal metastases targeting integrin α(v)β(3) expression in a syngeneic rat model. Eur J Surg Oncol 2011;37:252–257.
19.
Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Que I, Dijkstra J, Kaijzel EL, Prins F, Lowik CW, Smit VT, van de Velde CJ, Vahrmeijer AL: Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Res Treat 2010, E-pub ahead of print.
20.
Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL: Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 2008;30:782–789.
21.
Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr: In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375–378.
22.
Zhou H, Luby-Phelps K, Mickey BE, Habib AA, Mason RP, Zhao D: Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS One 2009;4:e8051.
23.
Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–6392.
24.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271–284.
25.
Hagen A, Grosenick D, Macdonald R, Rinneberg H, Burock S, Warnick P, Poellinger A, Schlag PM: Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions. Opt Express 2009;17:17016–17033.
26.
Intes X, Ripoll J, Chen Y, Nioka S, Yodh AG, Chance B: In vivo continuous-wave optical breast imaging enhanced with indocyanine green. Med Phys 2003;30:1039–1047.
27.
Alacam B, Yazici B, Intes X, Nioka S, Chance B: Pharmacokinetic-rate images of indocyanine green for breast tumors using near-infrared optical methods. Phys Med Biol 2008;53:837–859.
28.
Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, Hasegawa K, Beck Y, Fukayama M, Kokudo N: Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer 2009;115:2491–2504.
29.
Tagaya N, Shimoda M, Kato M, Nakagawa A, Abe A, Iwasaki Y, Oishi H, Shirotani N, Kubota K: Intraoperative exploration of biliary anatomy using fluorescence imaging of indocyanine green in experimental and clinical cholecystectomies. J Hepatobiliary Pancreat Surg 2009;17:595–600.
30.
Matsui A, Tanaka E, Choi HS, Winer JH, Kianzad V, Gioux S, Laurence RG, Frangioni JV: Real-time intra-operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically available contrast agents. Surgery 2010;148:87–95.
31.
Ishizawa T, Bandai Y, Ijichi M, Kaneko J, Hasegawa K, Kokudo N: Fluorescent cholangiography illuminating the biliary tree during laparoscopic cholecystectomy. Br J Surg 2010;97:1369–1377.
32.
Reuter SR, Redman HC, Bookstein JJ: Differential problems in the angiographic diagnosis of carcinoma of the pancreas. Radiology 1970;96:93–99.
33.
Komar G, Kauhanen S, Liukko K, Seppanen M, Kajander S, Ovaska J, Nuutila P, Minn H: Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009;15:5511–5517.
34.
Aoki T, Murakami M, Yasuda D, Shimizu Y, Kusano T, Matsuda K, Niiya T, Kato H, Murai N, Otsuka K, Kusano M, Kato T: Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography. J Hepatobiliary Pancreat Surg 2009;17:590–594.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.